Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Dec:22:15330338231208846.
doi: 10.1177/15330338231208846.

Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer

Yang Li  1   2 , Fangrong Shen  2 , Qingqing Tan  3 , Youguo Chen  2 , Yanzheng Gu  1
Affiliations
Review

Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer

Yang Li et al. Technol Cancer Res Treat. 2023 Jan-Dec.

Abstract

The mortality rate of cervical cancer is the highest among female malignant tumors and seriously threatens women's lives and health. Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer, which provides the basis for immunotherapy. In recent years, owing to progress in targeted therapy and immunotherapy, the survival time of patients with cervical cancer has been significantly extended. However, effective treatments for advanced, recurrent, and metastatic cancers are lacking. "Tumor immunotherapy" has been described as a viable option for tumor therapy but the efficacy of immunotherapy for cervical cancer has only been demonstrated in phase I or II clinical trials. Immune checkpoint inhibitors (ICIs) have shown promising clinical results particularly for treating recurrent and advanced cervical cancer, however, they remain inadequate in some patients. Immune checkpoint is the target of immunotherapy. Therefore, the identification of novel therapeutic targets is essential. In this paper, the structure, expression, function, biological effect of immune inhibitory receptors (IRs) and related clinical studies were reviewed, in order to further explore the application potential of these immune checkpoints and apply them to the future clinical treatment of cervical cancer.

Keywords: biomarker; cervical cancer; immune checkpoints; immunotherapy; inhibitory receptors.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Roles of LAG-3 in CD + 4 cells, CD + 8 cells, Treg cells and DC cells in tumor microenvironment.
See this image and copyright information in PMC

References

    1. Wang X, Huang X, Zhang Y, et al. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018;9:2896. doi:10.3389/fmicb.2018.02896 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide [J]. Curr Probl Cancer. 2018;42(5):457-465. doi:10.1016/j.currproblcancer.2018.06.003 - DOI - PubMed
    1. Tang XY, Shi AP, Xiong YL, et al. Clinical research on the mechanisms underlying immune checkpoints and tumor metastasis. Front Oncol. 2021;11:693321. doi:10.3389/fonc.2021.693321 - DOI - PMC - PubMed
    1. O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151-167. doi:10.1038/s41571-018-0142-8 - DOI - PubMed